These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 19841449)

  • 21. Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model.
    Dasbach EJ; Largeron N; Elbasha EH
    Expert Rev Pharmacoecon Outcomes Res; 2008 Oct; 8(5):491-500. PubMed ID: 20528334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlating immunity with protection for HPV infection.
    Frazer I
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S10-6. PubMed ID: 18162240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The human papillomavirus vaccines.
    Ljubojević S
    Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prophylactic HPV vaccination for women over 18 years of age.
    Adams M; Jasani B; Fiander A
    Vaccine; 2009 May; 27(25-26):3391-4. PubMed ID: 19200838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine.
    Barthell E; Woelber L; Hellner K; Camerer B; Gieseking F; Hauschild M; Mylonas I; Friese K; Sings HL; Railkar R; Gause C; Barr E
    Arch Gynecol Obstet; 2009 Jun; 279(6):803-7. PubMed ID: 18936950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ACP Journal Club. Adding HPV testing to cytology screening reduced ≥ grade 3 cervical intraepithelial neoplasia at 5 years.
    Budenholzer B
    Ann Intern Med; 2012 Jul; 157(2):JC2-6, JC2-7. PubMed ID: 22801698
    [No Abstract]   [Full Text] [Related]  

  • 27. Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States.
    Grant LA; Dunne EF; Chesson H; Markowitz LE
    Vaccine; 2011 Mar; 29(13):2365-70. PubMed ID: 21277406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cervical cancer prevention in the human papilloma virus vaccine era.
    Ghazal-Aswad S
    Ann N Y Acad Sci; 2008 Sep; 1138():253-6. PubMed ID: 18837904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected and uninfected women from Brazil.
    Nicol AF; Grinsztejn B; Friedman RK; Veloso VG; Cunha CB; Georg I; Pilotto JH; Moreira RI; Castro CA; Silver B; Viscidi RP
    J Clin Virol; 2013 Jun; 57(2):147-51. PubMed ID: 23490398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention strategies against human papillomavirus in males.
    Garland SM
    Gynecol Oncol; 2010 May; 117(2 Suppl):S20-5. PubMed ID: 20138347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
    Joura EA; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch X; Dillner J; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Lu S; Vuocolo S; Hesley TM; Haupt RM; Barr E
    Vaccine; 2008 Dec; 26(52):6844-51. PubMed ID: 18930097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HPV vaccination - a paradigm shift in public health.
    May J
    Aust Fam Physician; 2007 Mar; 36(3):106-11. PubMed ID: 17339969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and incidence of HPV genital infection in women.
    Velicer C; Zhu X; Vuocolo S; Liaw KL; Saah A
    Sex Transm Dis; 2009 Nov; 36(11):696-703. PubMed ID: 19652630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.
    Villa LL
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S17-25. PubMed ID: 18162241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ACP Journal Club. Quadrivalent HPV vaccine reduced risk for HPV infection and related disease in women 24 to 45 years of age.
    Granwehr BP
    Ann Intern Med; 2009 Oct; 151(8):JC4-12. PubMed ID: 19841449
    [No Abstract]   [Full Text] [Related]  

  • 36. ACP journal club. Quadrivalent HPV vaccine prevented HPV infection and external genital lesions in boys and men 16 to 26 years of age.
    Bender BS
    Ann Intern Med; 2011 May; 154(10):JC5-10. PubMed ID: 21576528
    [No Abstract]   [Full Text] [Related]  

  • 37. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials.
    Paavonen J;
    Curr Med Res Opin; 2008 Jun; 24(6):1623-34. PubMed ID: 18435868
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.